Sarepta Therapeutics

news

Vinay Prasad returns to lead vaccines and cell and gene therapy at the FDA

11 August 2025 | By Dominic Tyer (European Pharmaceutical Review)

CBER head makes surprise comeback just weeks after his abrupt resignation.

article

Amid FDA turmoil Sarepta’s gene therapy worries begin to ease

1 August 2025 | By Dominic Tyer (European Pharmaceutical Review)

But the impact of George Tidmarsh’s CBER appointment after Vinay Prasad’s abrupt resignation remains to be seen.

news

Gene therapy approved for Duchenne muscular dystrophy

23 June 2023 | By Catherine Eckford (European Pharmaceutical Review)

The first approved gene therapy for certain paediatric Duchenne muscular dystrophy (DMD) patients leads to production of the Elevidys micro-dystrophin protein.

news

Oligonucleotide synthesis market to reach $16.7 billion by 2027

9 December 2022 | By Catherine Eckford (European Pharmaceutical Review)

Ongoing clinical trials for oligonucleotide-based therapies will propel the oligonucleotide synthesis market to reach $16.7 billion by 2027, states a new report.

news

Complete response letter handed to Sarepta Therapeutics

20 August 2019 | By Victoria Rees (European Pharmaceutical Review)

The pharmaceutical company has received a complete response letter for its golodirsen injection, which had been submitted for accelerated approval.